This morning, Goldman Sachs lowered its price target on shares of MDC (NYSE:MDC) to $27 as the company is realizing smaller margins. With the lower price target, Goldman Sachs reduced its EPS estimates through 2013 and reiterated its neutral rating.
Shares of MDC were higher despite the report, gaining 0.7% this morning.
And Citigroup lowered its price target on shares of Allos Therapeutics (ALTH) from $7 down to $5 following the disappointing guidance from the company for 2011. With the lower price target, Citigroup did maintain its buy rating.
Shares of Allos were sharply lower on Wednesday, falling 12.1% today.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.